Healthcare Business - Page 2

Is InflaRx Sunk by a Midstage Skin Condition Study?

InflaRx N.V. (NASDAQ: IFRX) shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS). Prior to ...
Read Full Story »

How ReWalk’s Exo-Suit Is Breaking the Mold for Stroke Survivors

ReWalk Robotics Ltd. (NASDAQ: RWLK) shares absolutely exploded on Wednesday on news that the U.S. Food and Drug Administration (FDA) has cleared the firm's ReStore soft exo-suit system for sale ...
Read Full Story »

This Insulin ‘Tea Bag’ May Be a Game-Changer for Diabetics

A researcher at the University of Arizona, working in collaboration with other scientists across the country and in Canada, has been developing new technology that might mean diabetics will no ...
Read Full Story »

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

It has been a tough year for many members of the so-called big pharma and big biotech. Also, in recent years, the lines separating the largest biotechs from the largest ...
Read Full Story »

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Genocea Biosciences Inc. (NASDAQ: GNCA) is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO). The firm announced best-in-class clinical results from ...
Read Full Story »

Meet One of ASCO’s First Losers

Turning Point Therapeutics Inc. (NASDAQ: TPTX) shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients. The data came ...
Read Full Story »

Study: Health Care Costs Worry Americans More Than Any Other Financial Problem

As the cost of U.S. health care services and medications continue to grow at an alarming pace, Americans are now more likely to cite health care costs at their top ...
Read Full Story »

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics Inc. (NASDAQ: CARA) recently announced data from its late-stage trial in patients with chronic kidney disease (CKD). While there was a very positive reaction among investors, one analyst ...
Read Full Story »

These Are the States with the Best and Worst Hospitals for Patient Safety

Most people probably prefer to avoid going to the hospital if possible. It’s a choice of last resort, when we’re too sick for the doctor’s office, or need sophisticated tests ...
Read Full Story »

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca PLC (NASDAQ: AZN) would be scaled back. AstraZeneca subsidiary MedImmune is ...
Read Full Story »

Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside

Investors love when they find stocks that have the potential to rise 50% to 100% in a fairly short period. They just better keep in mind that they are probably ...
Read Full Story »

America’s Unsafe Medical Products

The U.S. Food and Drug Administration (FDA) has issued eight new safety alerts, comprising six related to product recalls, including one for an animal antibiotic; one regarding mortality rate among ...
Read Full Story »

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara Therapeutics Inc. (NASDAQ: CARA) shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Specifically, ...
Read Full Story »

Goldman Sachs Crushes Value and Turnaround Hopes of Gilead Sciences

Gilead Sciences Inc. (NASDAQ: GILD) quite recently has been considered as both a value stock and as a turnaround candidate for long-term views. Goldman Sachs has muted that upside view ...
Read Full Story »

Is This Kezar Life Sciences Lupus Study in Trouble?

Kezar Life Sciences Inc. (NASDAQ: KZR) shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE). The data ...
Read Full Story »